Natus Medical Inc (NASDAQ:BABY) has received a consensus rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $36.00.
Several equities analysts have recently issued reports on BABY shares. ValuEngine cut Natus Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. BidaskClub upgraded Natus Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 21st. Finally, Zacks Investment Research cut Natus Medical from a “hold” rating to a “strong sell” rating in a research report on Friday.
Get Natus Medical alerts:Natus Medical stock traded up $0.55 during mid-day trading on Tuesday, hitting $27.32. 1,149,516 shares of the company’s stock traded hands, compared to its average volume of 552,397. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.14 and a quick ratio of 1.89. The company has a market capitalization of $903.76 million, a P/E ratio of 19.24 and a beta of 0.58. Natus Medical has a one year low of $25.06 and a one year high of $37.95.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, February 13th. The medical equipment provider reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.07). Natus Medical had a negative net margin of 4.32% and a positive return on equity of 11.64%. The business had revenue of $141.00 million for the quarter, compared to the consensus estimate of $135.80 million. During the same period in the previous year, the firm earned $0.42 EPS. The firm’s revenue was up 7.3% on a year-over-year basis. On average, research analysts expect that Natus Medical will post 1.31 earnings per share for the current fiscal year.
In related news, Director Ken Ludlum sold 30,000 shares of Natus Medical stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $31.02, for a total value of $930,600.00. Following the transaction, the director now directly owns 73,957 shares in the company, valued at approximately $2,294,146.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert A. Gunst sold 14,750 shares of Natus Medical stock in a transaction on Monday, November 19th. The shares were sold at an average price of $33.54, for a total value of $494,715.00. Following the transaction, the director now owns 32,392 shares in the company, valued at approximately $1,086,427.68. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paloma Partners Management Co acquired a new stake in shares of Natus Medical in the third quarter worth about $218,000. Fenimore Asset Management Inc. increased its stake in shares of Natus Medical by 20.2% in the third quarter. Fenimore Asset Management Inc. now owns 392,145 shares of the medical equipment provider’s stock worth $13,980,000 after purchasing an additional 65,795 shares during the period. Rutabaga Capital Management LLC MA bought a new position in shares of Natus Medical in the third quarter worth about $9,272,000. Vaughan Nelson Investment Management L.P. bought a new position in shares of Natus Medical in the fourth quarter worth about $33,985,000. Finally, MetLife Investment Advisors LLC increased its stake in shares of Natus Medical by 52.4% in the third quarter. MetLife Investment Advisors LLC now owns 23,094 shares of the medical equipment provider’s stock worth $823,000 after purchasing an additional 7,937 shares during the period. 98.30% of the stock is owned by hedge funds and other institutional investors.
Natus Medical Company Profile
Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Featured Article: Google Finance
No comments:
Post a Comment